Despite a challenging 2024 for Boston’s life sciences market—marked by softening fundamentals and an oversupply of lab ...

This was the stock's second consecutive day of gains.

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on Immunocore Holdings (IMCR – Research Report) on April 11 and set a price target of ...

Vertex Pharmaceuticals earned well-deserved kudos after Dr. Paul Negulescu snagged the 2025 Canada Gairdner International ...